RADIUM RA-223 DICHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2Cl.Ra
Molecular Weight	293.924
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cl-].[Cl-].[223Ra++]

InChI

InChIKey=RWRDJVNMSZYMDV-SIUYXFDKSA-L

InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Ra
Molecular Weight	223.0185
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203971s007lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23653243; http://www.ncbi.nlm.nih.gov/pubmed/?term=23977665

Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Castrate-resistant prostate cancer 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203971s007lbl.pdf	Primary		Approved 8429	XOFIGO Approved Use Xofigo is an alpha particle-emitting radioactive thera peutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptoma tic bone metastases and no known visceral metastatic disease Launch Date 2013

PubMed

Title	Date	PubMed
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.	2008 Mar	18368304
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.	2013 Feb	23000088

Patents

Sample Use Guides

In Vivo Use Guide

The dose regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.

Route of Administration: Intravenous

In Vitro Use Guide

Radium-223 dichloride showed a dose-dependent inhibition of MDA-MB-231(SA) breast cancer cell proliferation at concentrations of 400, 800 and 1600 Bq/mLcompared to the control in a 5-day in vitro proliferation assay

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:25:31 GMT 2023` Edited by `admin` on `Fri Dec 15 17:25:31 GMT 2023`
Record UNII	RJ00KV3VTG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RADIUM RA-223 DICHLORIDE

Common Name

English

Radium Ra 223 dichloride [WHO-DD]

Common Name

English

ALPHARADIN

Common Name

English

BAY 88-8223

Code

English

RADIUM RA223 DICHLORIDE

Common Name

English

BAY88-8223

Code

English

BAY-88-8223

Code

English

RADIUM-223 CHLORIDE [MI]

Common Name

English

RADIUM CHLORIDE (223RACL2)

Common Name

English

RADIUM-223 DICHLORIDE

Common Name

English

RADIUM RA223 DICHLORIDE [EMA EPAR]

Common Name

English

RADIUM RA 223 DICHLORIDE [USAN]

Common Name

English

XOFIGO

Brand Name

English

RADIUM RA-223 DICHLORIDE [ORANGE BOOK]

Common Name

English

RADIUM RA 223 DICHLORIDE

Official Name

English

RADIUM CHLORIDE RA-223

Common Name

English

RADIUM-223 CHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129819